Male Breast Cancer In Family Leads To High Perception Of Risk, Low Likelihood Of Genetic Counseling

People with a family history of male breast cancer perceive themselves to be at higher risk of developing the disease than do patients with a family history of female breast cancer; however those with male breast cancer in their families are less likely to know about or seek genetic testing than those with a family [...]

Oral Contraceptives And Hormone Replacement Therapy May Protect Women Against Brain Aneurysms

Results from a new study suggest that oral contraceptives and hormone replacement therapy (HRT) may yield additional benefit of protecting against the formation and rupture of brain aneurysms in women…

Genetic Link Between Two Rare Diseases Established By Next Generation Sequencing

Scientists have successfully used “next generation sequencing” to identify mutations that may cause a rare and mysterious genetic disorder…

CMS to Consider Evidence on Bone Growth Agent

WASHINGTON (MedPage Today) — The Medicare Evidence Development and Coverage Advisory Committee (MEDCAC) will meet in September to consider available evidence for using bone morphogenetic protein (BMP) for a number of on-label and off-label uses.

Women Big Winners With Health Reform Law

(MedPage Today) — An estimated 30 million women will be helped by the new healthcare reform law over the next 10 years, according to a report from The Commonwealth Fund.

Stalled Stem Cell Trial for Spine Injury Cleared Again

(MedPage Today) — The on-again, off-again clinical trial of a human embryonic stem cell (hESC) therapy for spinal cord injury is on again, its sponsor said.

FDA Warns on Cure-All Product Based on Bleach

(MedPage Today) — The FDA has warned consumers not to use a product called Miracle Mineral Solution — which makes broad health claims — because it’s actually an industrial strength bleach.

FDA allows Geron’s planned Phase I clinical trial of GRNOPC1 in spinal cord injury to proceed

Geron Corporation announced today that the U.S. Food and Drug Administration (FDA) has notified the company that the clinical hold placed on Geron’s Investigational New Drug (IND) application has been lifted and the company’s Phase I clinical trial of GRNOPC1 in patients with acute spinal cord injury may proceed.

Pivotal PINNACLE trial results of VELCADE in patients with relapsed/refractory MCL released

Millennium: The Takeda Oncology Company today reported new correlative science data from the pivotal PINNACLE trial of VELCADE (bortezomib) in patients with relapsed/refractory mantle cell lymphoma. The data, derived from an analysis of archived tumor samples, tested pre-specified biomarkers for their association with time to progression and response to treatment with VELCADE in patients with [...]

Anadys Pharmaceuticals reports SVR12 data for ANA598

Anadys Pharmaceuticals, Inc. today announced that six of six patients (100%) in the ANA598 200 mg twice daily (bid) arm who were randomized to stop all treatment at Week 24 in an ongoing Phase II trial maintained undetectable levels of virus 12 weeks after stopping treatment, referred to as Sustained Virological Response 12, or SVR12.